Previous 10 | Next 10 |
Alkermes Completes Separation of Oncology Business PR Newswire — Alkermes Emerges as Pure-Play, Profitable Neuroscience Company — — Alkermes Provides Updated Financial Expectations for 2023 — DUBLIN , Nov. 15, 2023 /PRN...
NORTHAMPTON, MA / ACCESSWIRE / November 14, 2023 / This month, Alkermes acknowledges the important role of family members who are caregivers for their loved ones. We applaud your selflessness, dedication and unconditional love. Your efforts inspire us to continue developing innovative medicines ...
NORTHAMPTON, MA / ACCESSWIRE / November 13, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Product Stewardship and Environmental Impact Alkermes is committed to safe and sustainable research, development, manufacturing and commercialization...
NORTHAMPTON, MA / ACCESSWIRE / November 10, 2023 / Alkermes / Today and every day, we give thanks to all those providing care to loved ones. We recognize that caregiving can have an immense toll on one's overall well-being. If you or a loved one are a caregiver, it's important to know that you a...
2023-11-10 14:46:49 ET Summary Alkermes plans to spin out its oncology research division into a standalone entity, creating a potential value-unlocking transaction. The spin-off will allow Alkermes to focus on its neuroscience assets and cut $180 million of R&D spending, leadi...
NORTHAMPTON, MA / ACCESSWIRE / November 8, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Environmental Health, Safety and Security Alkermes is committed to operating in a manner that protects our employees, our environment and our communit...
2023-11-08 03:16:06 ET Summary Alkermes exhibits strong Q3 earnings with increased revenues and product sales; Lybalvi shows promising growth. Alkermes' ALKS-2680 enters a competitive narcolepsy market with a novel mechanism, necessitating observation for investment viability. ...
Alkermes to Participate in the Jefferies London Healthcare Conference PR Newswire DUBLIN , Nov. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conferen...
2023-11-06 08:40:13 ET More on Health Care Stocks Merck therapy shows improved survival in certain kidney cancer patients Pfizer: Ignore The Noise And Buy This Deep Value AstraZeneca to invest $245M in Cellectis to strengthen gene therapy portfolio Arexvy Put...
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement PR Newswire DUBLIN , Oct. 31 , 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural ...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...